A coalition of 27 states and the District of Columbia has taken legal action to prevent 23andMe from selling personal genetic data in its possession without customer consent.
The California-based biotechnology company filed for Chapter 11 bankruptcy on March 23 to facilitate the sale of its assets, sparking concerns over the handling of the sensitive genetic data it holds.